The Association between Myostatin and Sarcopenia in Liver Cirrhosis

Read full text Summarise with VIRAT
Authors: Komang Agus Wira Nugraha, I Ketut Mariadi, I Gusti Agung Suryadarma, Gde Somayana, Cokorde Istri Yuliandari Krisnawardani Kumbara
Cited by: 0
References: 34

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Sarcopenia is highly prevalent in patients with liver cirrhosis and contributes to decreased quality of life, increased morbidity, and mortality. The role of myostatin in cirrhosis-related sarcopenia remains controversial but may represent a potential therapeutic target. Objective: This study aimed to investigate the association between serum myostatin levels and sarcopenia in patients with liver cirrhosis. Methods: A cross-sectional study was conducted with 80 patients diagnosed with liver cirrhosis at Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia. Serum myostatin levels (ng/L) were measured using an ELISA technique. Sarcopenia was diagnosed based on the 2019 Asian Working Group for Sarcopenia (AWGS) consensus. Elevated myostatin levels were defined as values above the median. Bivariate and multivariate analyses were performed to assess associations between myostatin, cirrhosis severity, and sarcopenia. Results: The severity of cirrhosis (CTP B and C) was associated with elevated myostatin levels (PR = 2.046; 95% CI: 1.310-3.193; p = 0.002). Bivariate analysis demonstrated that elevated myostatin (PR = 2.178; 95% CI: 1.370-3.461; p

Fields of Study & Subjects

Nutrition and Health in Aging Liver Disease and Transplantation Muscle Physiology and Disorders

Publication details

Journal / source
Acta Medica Philippina
Volume
60
Issue
6
Pages
107–113
Publication date
25 February 2026
Language
EN